---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-011747"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:45:22.485462+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ORIC raises $125M in private placement; extends cash runway into late 2026

## Summary
- Sold 12.5M shares at $10.00 each; gross proceeds approx. $125M.
- Investors include Viking Global, Commodore, Frazier, Venrock, NEA, Nextech.
- Premium of ~10% to ORIC's 5-day trailing average price.
- Pro forma cash expected to fund operating plan into late 2026.
- Private placement expected to close on January 23, 2024.

## SEC filing metadata
- accession: 0001193125-24-011747
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312524011747/0001193125-24-011747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312524011747/d737340d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-011747
- JSON: https://secwatch.observer/filing/0001193125-24-011747.json
- Plain text: https://secwatch.observer/filing/0001193125-24-011747.txt

## Key facts
- Material Agreements
  Oric Pharmaceuticals, Inc. entered into Purchase Agreement with the purchasers named therein valued at 12,500,000 shares at $10.00 per Share, approximately $125 million aggregate gross proceeds (effective 2024-01-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: 12,500,000 shares at $10.00 per Share, approximately $125 million aggregate gross proceeds
  - Effective: 2024-01-20
  source text: On January 20, 2024, ORIC Pharmaceuticals, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at $10.00 per Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000119312524011747/0001193125-24-011747-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.